Stocksigma LogoStocksigma Logo

IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives

IOL Chemicals is investing ~INR 500 crore via internal accruals across three initiatives to drive an incremental 25–30% top-line growth by FY29 and achieve

IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives

IOL Chemicals & Pharmaceuticals Ltd · Transcript · 17 Sept 2026, 10:33 pm

IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives IOL Chemicals is investing ~INR 500 crore via internal accruals across three initiatives to drive an incremental 25–30% top-line growth by FY29 and achieve >15% company-wide ROCE. Capex includes expanding fully backward-integrated Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA (commissioning Dec'27), entering CDMO formulations with a 1,500 million tablets/annum EU-GMP certified facility (commercializing Q3 FY27), and setting up a dedicated specialty chemical tolling facility. Around 30% of funds are already deployed, with full utilization of new facilities targeted over 18–24 months post-commissioning.

Original exchange filing (PDF)

More announcements from IOL Chemicals & Pharmaceuticals Ltd

All IOL Chemicals & Pharmaceuticals Ltd announcements